News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Sergio Cifuentes: The Clinico-genomic Landscape and Outcomes of KRAS G12C–Mutated Pancreatic Cancer
Sergio Cifuentes Canabal/LinkedIn
Sep 24, 2024, 14:18

Sergio Cifuentes: The Clinico-genomic Landscape and Outcomes of KRAS G12C–Mutated Pancreatic Cancer

Sergio Cifuentes, Cancer Research Project Manager at CENEIT Mexico, shared on X:

“Check out my latest Insights – Characterizing the Clinico-genomic Landscape and Outcomes of KRAS G12C–Mutated Pancreatic Cancer.

Characterizing the Clinico-genomic Landscape and Outcomes of KRAS G12C–Mutated Pancreatic Cancer

  • Prevalence: KRAS is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS G12Cmut found in 1%-2% of pancreatic ductal adenocarcinoma cases.

Key Findings

  • The median age of the patients was 67, with 56% being female and a median BMI of 29.2 kg/m2. Sixty-seven percent had smoked at some point in their lives.
  • Survival Rates: Median overall survival was 13 months for stage IV and 26 months for stage I-III.
  • Commonly co-altered genes: TP53 (73%), CDKN2A (33%), SMAD4 (28%), and ARID1A (21%).
  • Overall survival did not differ between KRAS G12Cmut and non-G12C KRAS pancreatic ductal adenocarcinoma.

Clinical Implications

  • Distinct Phenotype: KRAS G12Cmut linked to unique clinical characteristics in pancreatic cancer.
  • Genomic Similarities: Resemblance to non-G12C KRAS mutations, highlighting the significance of ARID1A co-mutations.
  • Treatment Potential: Targeting KRAS G12C sets the stage for broader KRAS-focused therapies in pancreatic cancer.”

Sergio Cifuentes

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease 

Authors: Fergus Keane, Joanne F Chou, Henry Walch, Joshua Schoenfeld, Anupriya Singhal, Darren Cowzer, Emily Harrold, Catherine A O’Connor, Wungki Park, Anna Varghese, Imane El Dika, Fiyinfolu Balogun, Kenneth H Yu, Marinela Capanu, Nikolaus Schultz, Rona Yaeger, Eileen M O’Reilly,

Sergio Cifuentes

Source: Sergio Cifuentes/X

 

Anna Varghese Anupriya Singhal cancer Catherine A. O’Connor Darren Cowzer Eileen M. O'Reilly Emily Harrold Fergus Keane Fiyinfolu Balogun Henry Walch Imane El Dika Joanne F. Chou Joshua Schoenfeld Kenneth H Yu KRAS G12C–Mutated Pancreatic Cancer Marinela Capanu Nikolaus Schultz OncoDaily Oncology Pancreatic Cancer Rona Yaeger Sergio Cifuentes Wungki Park
Special Coverage
Insight
Dec 22, 2024, 00:21
Eric J. Small: ASCO/Conquer Cancer Foundation Felix Feng Prostate Cancer YIA is now fully endowed
Blog
Dec 21, 2024, 22:40
50 Years of History, a Future to Write Together - AIEOP
Science
Dec 21, 2024, 22:37
Breaking Down the Impact of Ionizing Radiation on Cancer
Blog
Dec 21, 2024, 22:35
Santiago Viteri: Latest findings from the BR.31 trial presented at the 2024 ESMO Congress
Blog
Dec 21, 2024, 22:33
ABIM will develop two new assessment options focusing on breast cancer and hematologic neoplasms
Blog
Dec 21, 2024, 22:28
Adekemi Oyewusi: EDUCARE - Supporting the medical treatment and education of those impacted by childhood cancer
Blog
Dec 21, 2024, 22:26
Anas Younes: Transforming outcomes for people living with Blood Cancer
Blog
Dec 21, 2024, 19:42
Ruben Mesa: Over 200 research staff of Atrium Health Wake Forest Baptist trained on Just Ask Increasing Diversity in Cancer Clinical Trials
Blog
Dec 21, 2024, 19:39
Kyaw Thein: Investigational Treatments for Thyroid and Head and Neck Cancers
Blog
Dec 21, 2024, 19:25
Hesham ElGhazaly: From an academic institution into a globally recognized hub for healthcare, research and innovation
Blog
Dec 21, 2024, 19:21
Douglas Flora: The 19 Words I’m Learning to Embrace as a Leader in 2025
Blog
Dec 21, 2024, 19:19
Registration and abstract submission open for the PTCOG63 - SIOP Europe